VitaSpring Biomedical Co. Ltd. Stock Other OTC
Equities
VSBC
US92851B1026
Biotechnology & Medical Research
Financials (USD)
Sales 2021 | 0.25 | Sales 2022 | 5.61 | Capitalization | 2.89B |
---|---|---|---|---|---|
Net income 2021 | - | Net income 2022 | 1M | EV / Sales 2021 | 2,936,169,226 x |
Net cash position 2021 | 45.4K | Net Debt 2022 | 356K | EV / Sales 2022 | 515,149,430 x |
P/E ratio 2021 |
-2,570
x | P/E ratio 2022 |
2,282
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 41.23% |
Managers | Title | Age | Since |
---|---|---|---|
Cheng Hsiang Kao
CEO | Chief Executive Officer | - | 20-01-20 |
Pao Chi Chu
CHM | Chairman | 70 | 20-01-20 |
Jer Li Lin
CTO | Chief Tech/Sci/R&D Officer | - | 20-01-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pao Chi Chu
CHM | Chairman | 70 | 20-01-20 |
1st Jan change | Capi. | |
---|---|---|
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |